Small Molecule Safety Assessment: Regulations, Risk, and CRO Considerations
Small molecule safety assessment is a critical step in developing new drugs. It is also an important opportunity to gather data that can be used to design and conduct clinical trials.
In this panel discussion, you will learn about:
- Our integrated drug development model and strategies to minimize risk, increase speed, and reduce cost
- How to navigate unexpected challenges in drug development
- How to mitigate risk and future-proof your drug development program
- Emerging trends in drug development: in vitro models
Presenters
Pete Gaskin, PhD, ERT, MTOPRA
Senior Director
Scientific Advisory Services, Charles River
Christine Copeman, BSc, Dip Ecotox
Senior Principal Scientific Advisor
Scientific Advisory Services, Charles River
Kyle Van Riper
Director Sales
Safety Assessment, Charles River